Kopach Olga, Krotov Volodymyr, Goncharenko Julia, Voitenko Nana
Laboratory of Sensory Signaling, Bogomoletz Institute of PhysiologyKyiv, Ukraine; Laboratory of Synaptic Imaging, Institute of Neurology, University College LondonLondon, UK.
Laboratory of Sensory Signaling, Bogomoletz Institute of Physiology Kyiv, Ukraine.
Front Cell Neurosci. 2016 Feb 29;10:50. doi: 10.3389/fncel.2016.00050. eCollection 2016.
Upregulation of Ca(2+)-permeable AMPA receptors (CP-AMPARs) in the dorsal horn (DH) neurons of the spinal cord has been causally linked to the maintenance of persistent inflammatory pain. Therefore, inhibition of CP-AMPARs could potentially alleviate an, otherwise, poorly treatable chronic pain. However, a loss of CP-AMPARs could produce considerable side effects because of the crucial role of CP-AMPARs in synaptic plasticity. Here we have tested whether the inhibition of spinal CP-AMPARs with dicationic compounds, the open-channel antagonists acting in an activity-dependent manner, can relieve inflammatory pain without adverse effects being developed. Dicationic compounds, N1-(1-phenylcyclohexyl)pentane-1,5-diaminium bromide (IEM-1925) and 1-trimethylammonio-5-1-adamantane-methyl-ammoniopentane dibromide (IEM-1460) were applied intrathecally (i.t.) as a post-treatment for inflammatory pain in the model of complete Freund's adjuvant (CFA)-induced long-lasting peripheral inflammation. The capability of dicationic compounds to ameliorate inflammatory pain was tested in rats in vivo using the Hargreaves, the von Frey and the open-field tests. Treatment with IEM-1460 or IEM-1925 resulted in profound alleviation of inflammatory pain. The pain relief appeared shortly after compound administration. The effects were concentration-dependent, displaying a high potency of dicationic compounds for alleviation of inflammatory hyperalgesia in the micromolar range, for both acute and long-lasting responses. The period of pain maintenance was shortened following treatment. Treatment with IEM-1460 or IEM-1925 changed neither thermal and mechanical basal sensitivities nor animal locomotion, suggesting that inhibition of CP-AMPARs with dicationic compounds does not give rise to detectable side effects. Thus, the ability of dicationic compounds to alleviate persistent inflammatory pain may provide new routes in the treatment of chronic pain.
脊髓背角(DH)神经元中钙离子通透型AMPA受体(CP-AMPARs)的上调与持续性炎性疼痛的维持存在因果关系。因此,抑制CP-AMPARs可能会缓解原本难以治疗的慢性疼痛。然而,由于CP-AMPARs在突触可塑性中起关键作用,CP-AMPARs缺失可能会产生相当大的副作用。在此,我们测试了使用双价化合物(以活性依赖方式起作用的开放通道拮抗剂)抑制脊髓CP-AMPARs是否能缓解炎性疼痛而不产生不良反应。双价化合物N1-(1-苯基环己基)戊烷-1,5-二溴化铵(IEM-1925)和1-三甲基铵-5-1-金刚烷甲基铵戊烷二溴化物(IEM-1460)经鞘内注射(i.t.),作为完全弗氏佐剂(CFA)诱导的长期外周炎症模型中炎性疼痛的后期治疗。使用哈格里夫斯试验、von Frey试验和旷场试验在大鼠体内测试双价化合物改善炎性疼痛的能力。用IEM-1460或IEM-1925治疗可显著减轻炎性疼痛。给药后不久即出现疼痛缓解。这些作用呈浓度依赖性,显示双价化合物在微摩尔范围内对缓解炎性痛觉过敏具有高效力,对急性和长期反应均如此。治疗后疼痛维持期缩短。用IEM-1460或IEM-1925治疗既不改变热和机械基础敏感性,也不改变动物运动,这表明用双价化合物抑制CP-AMPARs不会产生可检测到的副作用。因此,双价化合物缓解持续性炎性疼痛的能力可能为慢性疼痛的治疗提供新途径。